Advancing Next-Generation TCEs with AI-Guided Drug Design

• Exploring why new TCE designs such as dual targeting or avidity-based formats are required to overcome the challenges to TCE efficacy posed by solid tumors
• Building a deeper understanding of the affinity and epitope requirements that maximize tumor selectivity which will be critical to unlock the potential of dual targeting TCEs
• AI integration is profoundly impacting therapeutic discovery, enabling delivery of optimized candidates at breakthrough speed

Speakers:

Edwina Naik

Associate Director, Oncology Research

Amgen Inc.